Navigation Links
Bullet Bio Provides Update On Recent Financing And Results From Proof-Of-Concept Study For Lead Product Candidate
Date:9/12/2013

MENLO PARK, Calif., Sept. 12, 2013 /PRNewswire/ -- Bullet Biotechnology, Inc., a company developing an active immunotherapy for B-cell lymphomas, announced that it completed the final close of its Series A financing in June, bringing the total amount raised since the company's founding in September 2011 to approximately $2.5 million. The additional Series A funding will be used to support additional preclinical research and to further prepare the company's active immunotherapy for an Investigational New Drug (IND) application. 

The company also announced that preliminary in-vivo data from a study of several of its active immunotherapy product candidates in tumor-bearing mice demonstrated a significant survival advantage over control vaccinations.  After reviewing the results, Ronald Levy, MD, Bullet Bio Clinical Advisory Board Member, said, "This animal experiment is very encouraging for Bullet's technology.  It suggests that the Bullet idiotype vaccine is superior to the previous 'gold standard.'"

Bullet Bio's study using the 38C13 mouse model of lymphoma was conducted by Aragen Bioscience, Inc., headquartered in Morgan Hill, CA.  In addition to the in-vivo proof of concept studies, Aragen also conducted the initial manufacturing process development and product characterization of Bullet Bio's idiotype vaccine.  Bullet Bio and Aragen are continuing to further develop manufacturing and analytical methods for Bullet Bio's vaccine in preparation for clinical trials. Bullet Bio is continuing to analyze the results of the study while aggressively moving forward with Aragen on further preclinical in-vivo and in-vitro studies as manufacturing methods are prepared for clinical trials. 

"I am very excited with our progress and with the investors we've added to the Bullet Bio family. Our vision is a world where patients have better options, where a finely targeted, personalized immunotherapy can be used instead of the carpet-bombing chemotherapy approach. We're working very hard to start clinical trials in 2015 to demonstrate the safety and efficacy of our product and ultimately get to patients as quickly as we can," said Willie Quinn, President & CEO of Bullet Bio.

About Active Immunotherapy in B-Cell Lymphomas

In 2013, nearly 70,000 patients will be diagnosed in the US and Europe with incurable B-cell lymphomas, including Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma.  More than 60% of CLL patients are asymptomatic when diagnosed, and the standard of care is to observe these patients until the severity of symptoms warrants treatment. Although modern drugs, including antibodies and kinase inhibitors, improve outcomes, mortality for B-cell lymphomas remains high. Standard treatment often leads to chemotherapy and is accompanied by infection, bleeding, fatigue and other side effects.

Bullet Bio is working to develop an active immunotherapy that would be safe enough to be given to asymptomatic patients and powerful enough to change the course of their disease by harnessing the power of their own immune system.

About Bullet Biotechnology

Bullet Biotechnology, Inc. is a privately-held biotechnology company researching and developing active immunotherapies for patients with cancers and autoimmune diseases. Bullet Bio's lead product, BB-001, is a fully personalized active immunotherapy that uses a unique marker on B-cell lymphoma cells, the idiotype protein, to train a patient's own immune system to target their cancer cells.


'/>"/>
SOURCE Bullet Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Comments on Insurance Policy Bulletin
2. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
4. MetaStat Announces Stock Trading on OTC Bulletin Board
5. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
6. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
7. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
10. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
11. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):